Patents by Inventor Eric Marcusson
Eric Marcusson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10301627Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: November 15, 2017Date of Patent: May 28, 2019Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20180305691Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: ApplicationFiled: April 16, 2018Publication date: October 25, 2018Applicant: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Patent number: 9970009Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: GrantFiled: February 24, 2017Date of Patent: May 15, 2018Assignee: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Publication number: 20180127755Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: November 15, 2017Publication date: May 10, 2018Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9845470Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: October 26, 2016Date of Patent: December 19, 2017Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20170240891Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: ApplicationFiled: February 24, 2017Publication date: August 24, 2017Applicant: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Patent number: 9688985Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: GrantFiled: January 14, 2016Date of Patent: June 27, 2017Assignee: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Publication number: 20170137811Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 26, 2016Publication date: May 18, 2017Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9506062Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: August 24, 2015Date of Patent: November 29, 2016Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20160244753Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: ApplicationFiled: January 14, 2016Publication date: August 25, 2016Inventors: Balkrishen Bhat, Eric Marcusson
-
Patent number: 9267137Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: GrantFiled: January 15, 2015Date of Patent: February 23, 2016Assignee: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Publication number: 20160046941Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: August 24, 2015Publication date: February 18, 2016Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9150857Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: January 30, 2014Date of Patent: October 6, 2015Assignees: Regulus Therapeutics, Rosetta Genomics, Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20150218558Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: ApplicationFiled: January 15, 2015Publication date: August 6, 2015Inventors: Balkrishen Bhat, Eric Marcusson
-
Patent number: 8969317Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: GrantFiled: April 24, 2013Date of Patent: March 3, 2015Assignee: Regulus Therapeutics Inc.Inventors: Balkrishen Bhat, Eric Marcusson
-
Publication number: 20140206854Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: January 30, 2014Publication date: July 24, 2014Applicants: ROSETTA GENOMICS LTD., REGULUS THERAPEUTICS INC.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 8680067Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: May 25, 2012Date of Patent: March 25, 2014Assignees: Regulus Therapeutics, Inc., Rosetta Genomics LtdInventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20130289093Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.Type: ApplicationFiled: April 24, 2013Publication date: October 31, 2013Applicant: REGULUS THERAPEUTICS INC.Inventors: Balkrishen Bhat, Eric Marcusson
-
Publication number: 20110251150Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 29, 2008Publication date: October 13, 2011Applicants: Rosetta Genomics Ltd.Inventors: C. Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20070066549Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.Type: ApplicationFiled: September 17, 2004Publication date: March 22, 2007Inventors: Susan Freier, Kenneth Dobie, Eric Marcusson, Eric Swayze, Balkrishen Bhat, Jeremy Graff, Bruce Konicek